Wall Street brokerages expect that Seelos Therapeutics Inc (NASDAQ:SEEL) will announce earnings per share (EPS) of ($0.11) for the current fiscal quarter, according to Zacks. Zero analysts have issued estimates for Seelos Therapeutics’ earnings. Seelos Therapeutics reported earnings of ($0.09) per share during the same quarter last year, which would indicate a negative year-over-year growth rate of 22.2%. The firm is scheduled to announce its next earnings results on Thursday, August 6th.
According to Zacks, analysts expect that Seelos Therapeutics will report full-year earnings of ($0.44) per share for the current fiscal year. For the next year, analysts expect that the company will report earnings of ($0.47) per share. Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of research firms that that provide coverage for Seelos Therapeutics.
Seelos Therapeutics (NASDAQ:SEEL) last issued its earnings results on Thursday, May 7th. The company reported ($0.14) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.16) by $0.02.
SEEL traded down $0.09 on Friday, hitting $1.16. The company had a trading volume of 1,291,138 shares, compared to its average volume of 971,854. Seelos Therapeutics has a 12-month low of $0.42 and a 12-month high of $1.98. The business’s fifty day simple moving average is $1.13 and its 200 day simple moving average is $0.93.
A number of large investors have recently modified their holdings of the stock. Sabby Management LLC bought a new position in Seelos Therapeutics in the first quarter worth approximately $249,000. 1492 Capital Management LLC bought a new position in Seelos Therapeutics in the first quarter worth approximately $74,000. BlackRock Inc. raised its stake in Seelos Therapeutics by 5.8% in the first quarter. BlackRock Inc. now owns 427,449 shares of the company’s stock worth $210,000 after buying an additional 23,393 shares in the last quarter. Finally, Renaissance Technologies LLC raised its stake in Seelos Therapeutics by 10.8% in the fourth quarter. Renaissance Technologies LLC now owns 1,118,623 shares of the company’s stock worth $1,499,000 after buying an additional 108,665 shares in the last quarter. 11.53% of the stock is owned by institutional investors.
Seelos Therapeutics Company Profile
Seelos Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing technologies and therapeutics for the treatment of central nervous system, respiratory, and other disorders. The company is focused on neurological and psychiatric disorders, including orphan indications. Its lead programs are SLS-002, an intranasal racemic ketamine for the treatment of suicidality in post-traumatic stress disorder and in depressive disorder; and SLS-006, a partial dopamine agonist for monotherapy in early stage Parkinson's disease patients.
See Also: What is a Roth IRA?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Seelos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seelos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.